Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye
Rheumatology (Bulgaria) · 01.05.2026 · 34 (1) · 4-20
DOI: 10.35465/wx09tq86 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology (Bulgaria), online erschienen am 01.05.2026. Verfasst von Dilara Bulut Gökten und 1 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Biosimilar infliximab agents are increasingly used in the management of axial spondyloarthritis (axSpA), primarily driven by cost considerations. While clinical outcomes after switching from originator infliximab (INF) to several biosimilars have been reported, real-world data regarding switching to Ixifi remain limited.
Objectives
To evaluate clinical outcomes, treatment retention and safety following non-medical switching from originator INF to the biosimilar Ixifi in patients with axSpA.
Methods
This single-center observational cohort study included adult patients with axSpA who were transitioned from originator INF to Ixifi for non-medical reasons. Clinical assessments and laboratory parameters were recorded at baseline and at 3 and 6 months after switching. Disease activity was evaluated using ASDAS, BASDAI and BASFI. Safety outcomes and treatment discontinuation were systematically recorded.
Results
72 patients were included. Inflammatory markers, including C-reactive protein and erythrocyte sedimentation rate, remained stable over 6 months (p>0.05 for all), as did ASDAS scores (p>0.05). In contrast, BASDAI and BASFI showed modest but statistically significant improvements at month 6 (p=0.008 and p=0.002, respectively). 2 serious infections (2.8%) and 2 infusion reactions (2.8%) were observed. Treatment discontinuation occurred in 13.9% of patients, exclusively due to loss of efficacy. The estimated 6-month treatment retention rate was 86.1%.
Conclusion
In this real-world cohort, non-medical switching from originator infliximab to Ixifi in axSpA was associated with maintained short-term clinical stability, acceptable treatment retention and a favorable safety profile. However, the absence of a control group limits causal interpretation of these findings. Larger studies with longer follow-up are warranted to confirm long-term outcomes.
Zitieren
APA
Gökten, D. B., & Mercan, R. (2026). Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye. Rheumatology (Bulgaria), 34(1), 4-20. https://doi.org/10.35465/wx09tq86
Vancouver
Gökten DB, Mercan R. Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye. Rheumatology (Bulgaria). 2026;34(1):4-20. doi:10.35465/wx09tq86
BibTeX
@article{Gkten2026,
author = {Gökten, Dilara Bulut and Mercan, Rıdvan},
title = {Clinical Outcomes after Switching from Originator Infliximab to the Biosimilar Ixifi in Patients with Axial Spondyloarthritis: A Single-Center Study from Türkiye},
journal = {Rheumatology (Bulgaria)},
year = {2026},
volume = {34},
number = {1},
pages = {4--20},
doi = {10.35465/wx09tq86}
}
EUVIMED